---
title: "Gossamer Bio, Inc. (GOSS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/GOSS.US.md"
symbol: "GOSS.US"
name: "Gossamer Bio, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T17:14:22.110Z"
locales:
  - [en](https://longbridge.com/en/quote/GOSS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/GOSS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/GOSS.US.md)
---

# Gossamer Bio, Inc. (GOSS.US)

## Company Overview

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.gossamerbio.com](https://www.gossamerbio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:14.000Z

**Overall: D (0.71)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 288 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -55.42% |  |
| Net Profit YoY | -252.07% |  |
| P/B Ratio | -0.28 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 45225973.35 |  |
| Revenue | 55537000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 215.10% | A |
| Profit Margin | -324.82% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | -55.42% | E |
| Net Profit YoY | -252.07% | E |
| Total Assets YoY | -54.06% | E |
| Net Assets YoY | -2483.73% | E |
| Cash Flow Margin | 94.38% | C |
| OCF YoY | -55.42% | E |
| Turnover | 0.27 | D |
| Gearing Ratio | 225.28% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Gossamer Bio, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-55.42%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-252.07%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-0.28",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "45225973.35",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "55537000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "215.10%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-324.82%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-55.42%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-252.07%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-54.06%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-2483.73%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "94.38%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-55.42%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.27",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "225.28%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.25 | 99/386 | - | - | - |
| PB | -0.28 | 467/386 | - | - | - |
| PS (TTM) | 0.81 | 17/386 | 15.03 | 11.30 | 2.16 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 13% |
| Overweight | 1 | 13% |
| Hold | 5 | 63% |
| Underweight | 1 | 13% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.21 |
| Highest Target | 15.00 |
| Lowest Target | 0.30 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/GOSS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/GOSS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/GOSS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/GOSS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**